What this means
This study is a trial that is still signing up people. It will test whether the pill may help vision or slow vision loss. It does not yet show whether the pill works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–75
- Where
- 1 site, including Texas
The science
- Registered title
- A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
- Trial ID
- NCT07812090 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Diabetic Macular Edema (DME)
- What is tested
- Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
- Sponsor
- BioAge Labs, Inc.
- Ages
- 18 Years to 75 Years
- Dates
- First posted Sep 10, 2026 · updated Sep 10, 2026
Registry summary
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.
Sites (1)
- Site 106, McAllen, Texas, United States